Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression

Journal of Psychopharmacology

Volumn 25, Issue 10, 2011, Pages 1344-1346

  Paslakis, Georgios ^a   Kopf, Daniel ^a   Westphal, Sabine ^b   Gilles, Maria ^a   Lederbogen, Florian ^a   Hamann, Bettina ^a   Heuser, Isabella ^a,c   Deuschle, Michael ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Amitriptyline; cardiovascular risk; lipoprotein(a); major depression; paroxetine

Indexed keywords

AMITRIPTYLINE; LIPOPROTEIN; PAROXETINE;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; FEMALE; HAMILTON SCALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; AGED; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PAROXETINE;

EID: 82955194833     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110382469     Document Type: Article

References (20)

1. Bennet A, Di AE, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008 ; 168: 598-608 (Pubitemid 351468395)
2. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004 ; 37: 333-343 (Pubitemid 38490450)
3. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000 ; 102: 1082-1085
4. Emanuele E, Carlin MV, D'Angelo A, Peros E, Barale F, Geroldi D, et al. Elevated plasma levels of lipoprotein(a) in psychiatric patients: a possible contribution to increased vascular risk. Eur Psychiatry. 2006 ; 21: 129-133 (Pubitemid 43324722)
5. Erqou S, Kaptoge S, Perry PL, Di AE, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009 ; 302: 412-423
6. Hamidifard S, Fakhari A, Mahboob S, Gargari BP. Plasma levels of lipoprotein (a) in patients with major depressive disorders. Psychiatry Res. 2009 ; 169: 253-256
7. Insull W, McGovern ME, Schrott H, Thompson P, Crouse JR, Zieve F, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med. 2004 ; 164: 1121-1127 (Pubitemid 38668992)
8. Kamstrup PR. Lipoprotein(a) and ischemic heart disease-A causal association? A review. Atherosclerosis. 2010 ; 211: 15-23
9. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008 ; 117: 176-184
10. Keller C. Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management. Ther Apher Dial. 2007 ; 11: 2-8
11. Kent LK, Shapiro PA. Depression and related psychological factors in heart disease. Harv Rev Psychiatry. 2009 ; 17: 377-388
12. Kopf D, Westphal S, Luley CW, Ritter S, Gilles M, Weber-Hamann B, et al. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol. 2004 ; 24: 527-531 (Pubitemid 39274207)
13. Kostner KM, Kostner GM. Factors affecting plasma lipoprotein(a) levels: role of hormones and other nongenetic factors. Semin Vasc Med. 2004 ; 4: 211-214 (Pubitemid 39433673)
14. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000 ; 23: 618-623 (Pubitemid 30321540)
15. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem. 2003 ; 49: 1785-1796 (Pubitemid 37340313)
16. Nielsen LB, Juul K, Nordestgaard BG. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler Thromb Vasc Biol. 1998 ; 18: 641-649 (Pubitemid 28177906)
17. Sarandol A, Sarandol E, Eker SS, Karaagac EU, Hizli BZ, Dirican M, et al. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30: 1103-1108 (Pubitemid 43928228)
18. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke. 2007 ; 38: 1959-1966 (Pubitemid 46847277)
19. Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry. 2006 ; 67: 1856-1861 (Pubitemid 46048182)
20. Weber-Hamann B, Gilles M, Schilling C, Onken V, Frankhauser P, Kopf D, et al. Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. J Clin Psychopharmacol. 2008 ; 28: 581-584